Gain Therapeutics, Inc. (GANX) Stock Price & Analysis
Gain Therapeutics, Inc. (GANX) fell 2.37% to USD 1.65 as of June 10, 2026 at 12:17 UTC, according to Nexqual real-time market data.
GANX last closed at USD 1.69; the session ranged USD 1.56–1.7 on volume of 1,288,947 shares. Market capitalization is $70.38M, with a 52-week range of USD 1.41–4.34 (NGM). Source: Nexqual, June 10, 2026 at 12:17 UTC.
Key Statistics (as of June 10, 2026 at 12:17 UTC)
| Price | USD 1.65 |
|---|---|
| Change | ▼ 2.37% (down) |
| Previous Close | USD 1.69 |
| Open | USD 1.67 |
| Day Range | USD 1.56 – 1.7 |
| 52-Week Range | USD 1.41 – 4.34 |
| Volume | 1,288,947 shares |
| Market Cap | $70.38M |
| Exchange | NGM |
Technical Analysis (GANX)
Nexqual's technical model rates GANX "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 12:17 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.56 (neutral) |
| vs SMA50 | Below (USD 1.86) |
| MACD | -0.03 (negative) |
Analyst Ratings (GANX)
Wall Street analysts rate GANX "Strong Buy" based on 5 analysts, with a mean price target of USD 7.2 (range USD 5–8), per Nexqual as of June 10, 2026 at 12:17 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7.2 |
| High Target | USD 8 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (GANX)
| EPS Estimate | USD -0.15 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.14 ▲ beat |
| 2025-12-31 | USD -0.11 vs est -0.15 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.19 vs est -0.17 ▼ miss |
Source: Nexqual, June 10, 2026 at 12:17 UTC.
Financials & Fundamentals (GANX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -214.69% |
| Debt / Equity | 4.8 |
| Current Ratio | 4.69 |
| Total Cash | $16.54M |
| Total Debt | $672,302 |
| Free Cash Flow | $-11.12M |
Source: Nexqual, June 10, 2026 at 12:17 UTC.
Financial Health Score (GANX)
Nexqual rates Gain Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 12:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $17M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$19M |
| Efficiency | Critical — ROE -215%, ROA -81.2% |
Ownership (GANX)
| Insider Ownership | +2.29% |
|---|---|
| Institutional Ownership | +19.25% |
| Shares Outstanding | 42.65M |
| Float | 41.65M |
| Short % of Float | +7.67% |
Source: Nexqual, June 10, 2026 at 12:17 UTC.
Leadership (GANX)
Gain Therapeutics, Inc. is led by Gene Mack (age 51), President, CEO & Director, per Nexqual as of June 10, 2026 at 12:17 UTC.
| President, CEO & Director | Gene Mack (age 51) |
|---|---|
| Chairman & Founder | Khalid Islam (age 70) |
| Senior Vice President of Technical Operations | Terenzio Ignoni Pharm.D. |
| Senior Vice President of Research | Joanne Taylor |
Major Backers & Investors (GANX)
Notable institutional backers of Gain Therapeutics, Inc. include Marshall Wace LLP, Potomac Capital Management, Inc., Jones Financial Companies, L.L.L.P., according to Nexqual as of June 10, 2026 at 12:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Marshall Wace LLP | 4.15% |
| Potomac Capital Management, Inc. | 2.36% |
| Jones Financial Companies, L.L.L.P. | 1.48% |
| Cambridge Investment Research Advisors Inc. | 1.33% |
| DME Capital Management, LP | 1.33% |
| Susquehanna International Group, LLP | 1.01% |
| Fidelity | 0.85% |
| GSA Capital Partners LLP | 0.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.42% |
| Geode Capital | 1.05% |
Source: Nexqual, June 10, 2026 at 12:17 UTC.
From Gain Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
- The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
- Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation.
- The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FNCHQ | Finch Therapeutics Group, Inc. | USD 7.45 | ▲ 0% |
| CNTB | Connect Biopharma Holdings Limi | USD 2.12 | ▼ 2.3% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| COYA | Coya Therapeutics, Inc. | USD 4.48 | ▲ 1.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:17 UTC. This page is informational and not investment advice.